KIF3C与胶质瘤患者良好预后相关并可能受PI3K/AKT/mTOR通路调控
本研究分析53例WHO I-IV级胶质瘤患者的临床特征,用免疫组化评估KIF3C表达并比较高低表达组生存,另用TCGA数据库验证并用Oncomine公共数据库分析机制。低级别胶质瘤组KIF3C蛋白表达高于高级别胶质瘤组(P<0.05),KIF3C高表达者生存时间更长(P<0.05),低级别胶质瘤亚组中高表达者生存时间更长(P<0.05)。生物信息学分析显示PI3K/AKT/mTOR通路抑制后KIF3C mRNA表达显著上调。
要点
- 低级别胶质瘤组(n=20)KIF3C蛋白表达高于高级别胶质瘤组(n=33)(P<0.05)。
- KIF3C高表达胶质瘤患者生存时间更长(P<0.05),低级别胶质瘤亚组同样(P<0.05)。
- PI3K/AKT/mTOR通路抑制后KIF3C mRNA表达显著上调,KIF3C可能抑制胶质瘤生长。
核心结论
- 本研究提示KIF3C可能通过调控PI3K/AKT/mTOR通路抑制胶质瘤生长以延长生存时间,为胶质瘤的潜在治疗靶点。
研究设计与样本
- 分析53例WHO I-IV级胶质瘤患者的临床特征,用免疫组化评估KIF3C表达,比较高低表达组生存,并用TCGA数据库验证,用Oncomine公共数据库分析调控机制。
主要发现
- 低级别胶质瘤组(n=20)KIF3C蛋白表达高于高级别胶质瘤组(n=33)(P<0.05)。
- KIF3C高表达胶质瘤患者生存时间更长(P<0.05)。
- 亚组分析显示低级别胶质瘤组中KIF3C高表达者生存时间更长(P<0.05)。
- 上述临床结果与TCGA数据库一致。
- 生物信息学分析显示PI3K/AKT/mTOR通路抑制后KIF3C mRNA表达显著上调。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioma is the most common malignant primary tumor in the central nervous system (CNS). KIF3C, a motor protein of the kinesin superfamily, is highly expressed in the CNS. Although KIF3C has been identified as a potential therapeutic target in malignant cancers, the expression and function of KIF3C in glioma remains unclear. METHODS: The clinical characteristics of 53 patients with graded glioma (WHO I-IV) were analyzed in this study. The expression of KIF3C in glioma was evaluated by immunohistochemistry (IHC). Survival analysis was compared between higher and lower KIF3C expression groups. Data regarding the expression of KIF3C and survival analysis were also confirmed using the database from The Cancer Genome Atlas (TCGA). The potential mechanism of the regulation of tumor growth by KIF3C was investigated by an analysis of the public database from Oncomine. RESULTS: Expression of the KIF3C protein was higher in the low-grade glioma (LGG) group (n = 20) than that in the high-grade glioma (HGG) group (n = 33) (P < 0.05). Glioma patients with higher expression of KIF3C had longer survival time (P < 0.05). The subgroup analysis showed that higher KIF3C expression predicted longer survival time in the LGG group (P < 0.05). These clinical results were consistent with those in the TCGA database. Bioinformatics analysis showed that the KIF3C mRNA expression was upregulated significantly in response to PI3K/AKT/mTOR pathway inhibition. CONCLUSION: This study demonstrated that KIF3C might inhibit glioma growth to prolong survival time by regulating the PI3K/AKT/mTOR pathway, providing a potential therapeutic target in glioma.
引用
- Gao Y, Li L, Zheng H, et al. KIF3C is associated with favorable prognosis in glioma patients and may be regulated by PI3K/AKT/mTOR pathway. J Neurooncol. 2020. PMID: 32020481. doi:10.1007/s11060-020-03399-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。